Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized treatment modalities for patients with relapsed/refractory hematologic cancers.1 As CAR-T therapy becomes more widely applied, toxic effects unique to CAR-T treatment are being identified that may potentially affect any organ or system.2 We report a case of a cutaneous toxic reaction after CAR-T therapy.
Hu Y, Zheng W, Qiao J, et al. Bullous and Exanthematous Lesions Associated With Chimeric Antigen Receptor T-Cell Therapy in a Patient With Diffuse Large B-Cell Lymphoma. JAMA Dermatol. 2020;156(9):1026–1028. doi:10.1001/jamadermatol.2020.0636
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.